Klea HoldingSTU:7V91 +2.55%44 EBITDA Margin % is 24.66% as of Dec. 2025. GuruFocus rates STU:7V91 with a GF Score™ of 44/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Klea Holding ranks better than 79.8% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Klea Holding's EBITDA for the
six
months ended in Dec. 2025 was €2.64 Mil. Klea Holding's Revenue for the
six
months ended in Dec. 2025 was €10.71 Mil. Therefore, Klea Holding's EBITDA margin for the quarter that ended in Dec. 2025 was 24.66%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Klea Holding EBITDA Margin % Related Terms
Klea Holding EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Klea Holding's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7V91 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Klea Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klea Holding EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Klea Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Klea Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klea Holding (STU:7V91) has a EBITDA Margin % of 24.66% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Klea Holding and its competitors. According to the industry distribution chart, Klea Holding ranks #41 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 20.2%.
Is Klea Holding's EBITDA Margin % too high?
Klea Holding's current EBITDA Margin % is 24.66%. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Klea Holding's value of 24.66% is 393.2% above this industry median. Based on the distribution chart, Klea Holding ranks #41 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Klea Holding has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Klea Holding's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Klea Holding ranks #41 out of 203 companies for EBITDA Margin %. This places Klea Holding in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Klea Holding's value of 24.66% is 393.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Klea Holding's current EBITDA Margin % of 24.66% is 393.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Klea Holding and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klea Holding's current EBITDA Margin % is 24.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klea Holding stock overvalued right now?
Based on GuruFocus' analysis, Klea Holding (STU:7V91) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.18 — trading 44.8% below its estimated fair value. The current EBITDA Margin % is 24.66% and 393.2% above the Medical Diagnostics & Research industry median of 5.00. Klea Holding's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Klea Holding (STU:7V91), the current EBITDA Margin % is 24.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klea Holding (STU:7V91) Overvalued in 2026?
Based on GuruFocus' analysis, Klea Holding stock appears to be undervalued.
The current stock price of €0.18 is trading 44.8% below its estimated GF Value™ of €0.32.
GuruFocus considers Klea Holding to be Possible Value Trap.
Key valuation signals for STU:7V91:
EBITDA Margin %: 24.66%
GF Value™: €0.32 vs. price of €0.18 (44.8% below fair value)
Industry Position: 393.2% above the Medical Diagnostics & Research median (#41 of 203)
No single metric tells the full story. See the STU:7V91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klea Holding focused on the acquisition, development and digitalization of companies in multiple sectors. Its development of Smart Salem, the first network of digital medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the Emirates United Arabs, or its Smart Health joint venture developed in Saudi Arabia.
44GF Score
Get the complete analysis for STU:7V91
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7V91 has been successfully added to your 
